Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.
暂无分享,去创建一个
Louis P Garrison | Sean D Sullivan | David L Veenstra | Peter J Neumann | Josh J Carlson | L. Garrison | S. Sullivan | D. Veenstra | P. Neumann | J. Carlson
[1] K. Chalkidou,et al. Coverage with evidence development: A very good beginning, but much to be done. Commentary to Hutton et al. , 2007, International Journal of Technology Assessment in Health Care.
[2] Yoav Ben-Shlomo,et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator , 2009, BMJ : British Medical Journal.
[3] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[4] S. Chapman,et al. Outcomes guarantee for lipid-lowering drugs: results from a novel approach to risk sharing in primary care , 2004 .
[5] Richard Pazdur,et al. Accelerated approval of oncology products: a decade of experience. , 2004, Journal of the National Cancer Institute.
[6] J. Bryant,et al. Bortezomib for the treatment of multiple myeloma patients. , 2009, Health technology assessment.
[7] S. Tunis,et al. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. , 2006, Health affairs.
[8] R. Weintraub,et al. Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia , 2012, PharmacoEconomics.
[9] No cure, no pay , 2005, BMJ : British Medical Journal.
[10] J. Colquitt,et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. , 2008, Health technology assessment.
[11] Anthony O'Hagan,et al. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the future , 2009, BMC neurology.
[12] D. Chadwick,et al. Shared scheme for assessing drugs for multiple sclerosis :Dealing with uncertainties about cost effectiveness of treatments is difficult problem , 2003, BMJ : British Medical Journal.
[13] Peter Littlejohns,et al. Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. , 2007, Journal of the Royal Society of Medicine.
[14] Stephen Chapman,et al. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care , 2003, BMJ : British Medical Journal.
[15] S. Fishbane,et al. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients , 2005, Hemodialysis international. International Symposium on Home Hemodialysis.
[16] B. Jönsson. Relative effectiveness and the European pharmaceutical market , 2011, The European Journal of Health Economics.
[17] M. Ahern,et al. Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor‐α inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based? , 2006, Internal medicine journal.
[18] Christine Y. Lu,et al. The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines , 2007 .
[19] G. Frampton,et al. Evidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE , 2009 .
[20] A. Anell,et al. Reimbursement and clinical guidance for pharmaceuticals in Sweden , 2005, The European Journal of Health Economics.